{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:59:05Z","timestamp":1780099145709,"version":"3.54.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02631-3","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:42:02Z","timestamp":1750743722000},"page":"2599-2614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Time trends and health inequalities of cirrhosis caused by metabolic Dysfunction-associated steatotic liver disease from 1990 to 2021: A global burden of disease study"],"prefix":"10.1007","volume":"48","author":[{"given":"Min","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weinong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5112-9608","authenticated-orcid":false,"given":"Zhenxiang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"2631_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatol (Baltim Md) 78:1966\u20131986. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","journal-title":"Hepatol (Baltim Md)"},{"key":"2631_CR2","doi-asserted-by":"publisher","first-page":"g4596","DOI":"10.1136\/bmj.g4596","volume":"349","author":"N Sattar","year":"2014","unstructured":"Sattar N, Forrest E, Preiss D (2014) Non-alcoholic fatty liver disease. BMJ (Clin Res Ed) 349:g4596. https:\/\/doi.org\/10.1136\/bmj.g4596","journal-title":"BMJ (Clin Res Ed)"},{"key":"2631_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS (2023) Global burden of liver disease: 2023 update. J Hepatol 79:516\u2013537. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.017","journal-title":"J Hepatol"},{"key":"2631_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) (2024) European association for the study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"2631_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R et al (2024) The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc 22:1999\u20132010e8. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"key":"2631_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000735","author":"S Driessen","year":"2023","unstructured":"Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME et al (2023) Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatol (Baltim Md). https:\/\/doi.org\/10.1097\/HEP.0000000000000735","journal-title":"Hepatol (Baltim Md)"},{"key":"2631_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12933-024-02264-5","volume":"23","author":"C Boutari","year":"2024","unstructured":"Boutari C, Stefanakis K, Simati S, Guatibonza-Garc\u00eda V, Valenzuela-Vallejo L, Anastasiou IA et al (2024) Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity. Cardiovasc Diabetol 23:174. https:\/\/doi.org\/10.1186\/s12933-024-02264-5","journal-title":"Cardiovasc Diabetol"},{"key":"2631_CR8","doi-asserted-by":"publisher","first-page":"156028","DOI":"10.1016\/j.metabol.2024.156028","volume":"161","author":"X-F Zeng","year":"2024","unstructured":"Zeng X-F, Varady KA, Wang X-D, Targher G, Byrne CD, Tayyem R et al (2024) The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus. Metab Clin Exp 161:156028. https:\/\/doi.org\/10.1016\/j.metabol.2024.156028","journal-title":"Metab Clin Exp"},{"key":"2631_CR9","doi-asserted-by":"publisher","first-page":"107971","DOI":"10.1016\/j.ypmed.2024.107971","volume":"184","author":"S Zhang","year":"2024","unstructured":"Zhang S, Huo Z, Born\u00e9 Y, Meng G, Zhang Q, Liu L et al (2024) Adherence to a healthy lifestyle including sleep and sedentary behaviors and risk of metabolic dysfunction-associated steatotic liver disease in Chinese adults. Prev Med 184:107971. https:\/\/doi.org\/10.1016\/j.ypmed.2024.107971","journal-title":"Prev Med"},{"key":"2631_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","volume":"9","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Shang Y, Hegmar H, Nasr P (2024) Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol 9:944\u2013956. https:\/\/doi.org\/10.1016\/S2468-1253(24)00193-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2631_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7:851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2631_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol (Baltim Md) 64:73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatol (Baltim Md)"},{"key":"2631_CR13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatol (Baltim Md) 77:1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004","journal-title":"Hepatol (Baltim Md)"},{"key":"2631_CR14","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1111\/liv.70001","volume":"45","author":"EKJ Tham","year":"2025","unstructured":"Tham EKJ, Tan DJH, Danpanichkul P, Ng CH, Syn N, Koh B et al (2025) The global burden of cirrhosis and other chronic liver diseases in 2021. Liver Int: Off J Int Assoc Study Liver 45:e70001. https:\/\/doi.org\/10.1111\/liv.70001","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"key":"2631_CR15","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators","year":"2024","unstructured":"GBD 2021 Diseases and Injuries Collaborators (2024) Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet (Lond Engl) 403:2133\u20132161. https:\/\/doi.org\/10.1016\/S0140-6736(24)00757-8","journal-title":"Lancet (Lond Engl)"},{"key":"2631_CR16","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L (2025) Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 31:S32\u201350. https:\/\/doi.org\/10.3350\/cmh.2024.0431","journal-title":"Clin Mol Hepatol"},{"key":"2631_CR17","doi-asserted-by":"publisher","first-page":"113888","DOI":"10.1016\/j.addr.2021.113888","volume":"176","author":"V Kumar","year":"2021","unstructured":"Kumar V, Xin X, Ma J, Tan C, Osna N, Mahato RI (2021) Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev 176:113888. https:\/\/doi.org\/10.1016\/j.addr.2021.113888","journal-title":"Adv Drug Deliv Rev"},{"key":"2631_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"W-K Chan","year":"2023","unstructured":"Chan W-K, Chuah K-H, Rajaram RB, Lim L-L, Ratnasingam J, Vethakkan SR (2023) Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr 32:197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052","journal-title":"J Obes Metab Syndr"},{"key":"2631_CR19","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1053\/j.gastro.2023.01.040","volume":"164","author":"VL Chen","year":"2023","unstructured":"Chen VL, Oliveri A, Miller MJ, Wijarnpreecha K, Du X, Chen Y et al (2023) PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis. Gastroenterology 164:966\u2013977e17. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.040","journal-title":"Gastroenterology"},{"key":"2631_CR20","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.14336\/AD.2022.0318","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Adeniji NT, Fan W, Kunimoto K, T\u00f6r\u00f6k NJ (2022) Non-alcoholic fatty liver disease and liver fibrosis during aging. Aging Dis 13:1239\u20131251. https:\/\/doi.org\/10.14336\/AD.2022.0318","journal-title":"Aging Dis"},{"key":"2631_CR21","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstr\u00f6m H, Ludvigsson JF (2021) Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 70:1375\u20131382. https:\/\/doi.org\/10.1136\/gutjnl-2020-322786","journal-title":"Gut"},{"key":"2631_CR22","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1038\/s41598-025-93082-6","volume":"15","author":"BC Czapla","year":"2025","unstructured":"Czapla BC, Dalvi A, Hu J, Moran IJ, Wijarnpreecha K, Chen VL (2025) Physical activity, diet, and social determinants of health associate with health related quality of life and fibrosis in MASLD. Sci Rep 15:7976. https:\/\/doi.org\/10.1038\/s41598-025-93082-6","journal-title":"Sci Rep"},{"key":"2631_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"H-H Lee","year":"2024","unstructured":"Lee H-H, Lee HA, Kim E-J, Kim HY, Kim HC, Ahn SH et al (2024) Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut 73:533\u2013540. https:\/\/doi.org\/10.1136\/gutjnl-2023-331003","journal-title":"Gut"},{"key":"2631_CR24","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","volume":"111S","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G (2020) Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metab Clin Exp 111S:154170. https:\/\/doi.org\/10.1016\/j.metabol.2020.154170","journal-title":"Metab Clin Exp"},{"key":"2631_CR25","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1007\/s00392-023-02250-z","volume":"112","author":"C Roderburg","year":"2023","unstructured":"Roderburg C, Krieg S, Krieg A, Vaghiri S, Mohr R, Konrad M et al (2023) Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients. Clin Res Cardiol: Off J Ger Card Soc 112:1446\u20131453. https:\/\/doi.org\/10.1007\/s00392-023-02250-z","journal-title":"Clin Res Cardiol: Off J Ger Card Soc"},{"key":"2631_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3748\/wjg.v30.i7.652","volume":"30","author":"Q-J He","year":"2024","unstructured":"He Q-J, Li Y-F, Zhao L-T, Lin C-T, Yu C-Y, Wang D (2024) Recent advances in age-related metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 30:652\u2013662. https:\/\/doi.org\/10.3748\/wjg.v30.i7.652","journal-title":"World J Gastroenterol"},{"key":"2631_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E et al (2023) Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol 20:388\u2013398. https:\/\/doi.org\/10.1038\/s41575-023-00759-2","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2631_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11894-023-00883-8","volume":"25","author":"YC Ilagan-Ying","year":"2023","unstructured":"Ilagan-Ying YC, Banini BA, Do A, Lam R, Lim JK (2023) Screening, diagnosis, and staging of non-alcoholic fatty liver disease (NAFLD): application of society guidelines to clinical practice. Curr Gastroenterol Rep 25:213\u2013224. https:\/\/doi.org\/10.1007\/s11894-023-00883-8","journal-title":"Curr Gastroenterol Rep"},{"key":"2631_CR29","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.3390\/nu16203543","volume":"16","author":"FM Calabrese","year":"2024","unstructured":"Calabrese FM, Aloisio Caruso E, De Nunzio V, Celano G, Pinto G, Cofano M et al (2024) Metataxonomics and metabolomics profiles in metabolic dysfunction-associated fatty liver disease patients on a navelina orange-enriched diet. Nutrients 16:3543. https:\/\/doi.org\/10.3390\/nu16203543","journal-title":"Nutrients"},{"key":"2631_CR30","doi-asserted-by":"publisher","first-page":"CD015033","DOI":"10.1002\/14651858.CD015033.pub2","volume":"10","author":"H Wen","year":"2024","unstructured":"Wen H, Deng H, Yang L, Li L, Lin J, Zheng P et al (2024) Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev 10:CD015033. https:\/\/doi.org\/10.1002\/14651858.CD015033.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2631_CR31","doi-asserted-by":"publisher","first-page":"156028","DOI":"10.1016\/j.metabol.2024.156028","volume":"161","author":"X-F Zeng","year":"2024","unstructured":"Zeng X-F, Varady KA, Wang X-D, Targher G, Byrne CD, Tayyem R et al (2024) The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus. Metabolism 161:156028. https:\/\/doi.org\/10.1016\/j.metabol.2024.156028","journal-title":"Metabolism"},{"key":"2631_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH (2023) Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 20:708\u2013722. https:\/\/doi.org\/10.1038\/s41575-023-00800-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2631_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12875-023-02073-x","volume":"24","author":"L Brooks","year":"2023","unstructured":"Brooks L, Elliott J, Stolee P, Boscart VM, Gimbel S, Holisek B et al (2023) Development, successes, and potential pitfalls of multidisciplinary chronic disease management clinics in a family health team: a qualitative study. BMC Prim Care 24:126. https:\/\/doi.org\/10.1186\/s12875-023-02073-x","journal-title":"BMC Prim Care"},{"key":"2631_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.healthpol.2020.12.006","volume":"125","author":"D Pascucci","year":"2021","unstructured":"Pascucci D, Sassano M, Nurchis MC, Cicconi M, Acampora A, Park D et al (2021) Impact of interprofessional collaboration on chronic disease management: findings from a systematic review of clinical trial and meta-analysis. Health Policy (Amst Neth) 125:191\u2013202. https:\/\/doi.org\/10.1016\/j.healthpol.2020.12.006","journal-title":"Health Policy (Amst Neth)"},{"key":"2631_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/tmi.13696","volume":"27","author":"SE Kastberg","year":"2022","unstructured":"Kastberg SE, Lund HS, De Lucia-Rolfe E, Kaduka LU, Boit MK, Corpeleijn E et al (2022) Hepatic steatosis is associated with anthropometry, cardio-metabolic disease risk, sex, age and urbanisation, but not with ethnicity in adult Kenyans. Trop Med Int Health: TM IH 27:49\u201357. https:\/\/doi.org\/10.1111\/tmi.13696","journal-title":"Trop Med Int Health: TM IH"},{"key":"2631_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13293-022-00475-7","volume":"13","author":"S Fresneda","year":"2022","unstructured":"Fresneda S, Abbate M, Busquets-Cort\u00e9s C, L\u00f3pez-Gonz\u00e1lez A, Fuster-Parra P, Bennasar-Veny M et al (2022) Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study. Biol Sex Differ 13:64. https:\/\/doi.org\/10.1186\/s13293-022-00475-7","journal-title":"Biol Sex Differ"},{"key":"2631_CR37","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/CIA.S295524","volume":"16","author":"SA Alqahtani","year":"2021","unstructured":"Alqahtani SA, Schattenberg JM (2021) NAFLD in the elderly. Clin Interv Aging 16:1633\u20131649. https:\/\/doi.org\/10.2147\/CIA.S295524","journal-title":"Clin Interv Aging"},{"key":"2631_CR38","doi-asserted-by":"publisher","first-page":"mjad069","DOI":"10.1093\/jmcb\/mjad069","volume":"15","author":"H Chen","year":"2024","unstructured":"Chen H, Liu Y, Liu D, Liang Y, Zhu Z, Dong K et al (2024) Sex- and age-specific associations between abdominal fat and non-alcoholic fatty liver disease: A prospective cohort study. J Mol Cell Biol 15:mjad069. https:\/\/doi.org\/10.1093\/jmcb\/mjad069","journal-title":"J Mol Cell Biol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02631-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02631-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02631-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:04:48Z","timestamp":1762880688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02631-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2631"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02631-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflict of interest concerning this work to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}